title: [Treatment of non-cirrhotic, non-tumoural portal vein thrombosis].
abstract: Thrombosis of the splenoportal axis not associated with liver cirrhosis or neoplasms is a rare disease whose prevalence ranges from 0.7 to 3.7 per 100,000 inhabitants. However, this entity is the second most common cause of portal hypertension. Prothrombotic factors are present as an underlying cause in up to 70% of patients and local factors in 10-50%. The coexistence of several etiological factors is frequent. Clinical presentation may be acute or chronic (portal cavernomatosis). The acute phase can present as abdominal pain, nausea, vomiting, fever, rectorrhagia, intestinal congestion, and ischemia. In this phase, early initiation of anticoagulation is essential to achieve portal vein recanalization and thus improve patient prognosis. In the chronic phase, symptoms are due to portal hypertension syndrome. In this phase, the aim of treatment is to treat or prevent the complications of portal hypertension. Anticoagulation is reserved to patients with a proven underlying thrombophilic factor.
authors.affiliation: Hospital Universitario Puerta de Hierro Majadahonda, Madrid, España.
authors.forename: Elba
authors.initials: E
authors.lastname: Llop
authors.affiliation: CTO, Department of Medicine, Icahn School of Medicine at Mount Sinai, Nueva York, Estados Unidos. Electronic address: susana.seijo@mssm.edu.
authors.forename: Susana
authors.initials: S
authors.lastname: Seijo
mesh_terms: D000208:Acute Disease; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D001649:Bile Duct Diseases / Q000150:complications / Q000628:therapy; D002908:Chronic Disease; D003097:Collateral Circulation; D000072226:Computed Tomography Angiography; D004198:Disease Susceptibility; D004967:Estrogens / Q000009:adverse effects; D006471:Gastrointestinal Hemorrhage / Q000209:etiology; D006392:Hemangioma, Cavernous / Q000209:etiology; D006801:Humans; D006975:Hypertension, Portal / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D015994:Incidence; D008026:Ligation; D008113:Liver Neoplasms / Q000209:etiology; D018810:Magnetic Resonance Angiography; D011169:Portal Vein / Q000000981:diagnostic imaging; D019851:Thrombophilia / Q000150:complications; D018608:Ultrasonography, Doppler; D020246:Venous Thrombosis / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*
chemical_list: D000319:Adrenergic beta-Antagonists; D000925:Anticoagulants; D004967:Estrogens
keywords: Anticoagulación; Anticoagulation; Hemorragia digestiva varicosa; Hipertensión portal; JAK2V617F mutation; Mutación JAK2V617F; Myeloproliferative neoplasia; Neoplasia mieloproliferativa; Portal hypertension; Variceal gastrointestinal bleeding